The new data comes from the KEYLYNK-001 study evaluating Keytruda (pembrolizumab) and chemotherapy followed by Lynparza (olaparib) maintenance therapy with or without bevacizumab in patients with ...
RAHWAY, N.J., December 09, 2024--Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer RAHWAY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback